Navigation Links
PAREXEL International Reports Third Quarter Fiscal Year 2013 Results
Date:4/30/2013

$
50,611$
43,301% of total service revenue11.1%12.2%Gross profit$
20,187$
8,200Gross margin % of service revenue39.9%42.0%Perceptive Informatics (PI)Service revenue$
,495$
49,319% of total service revenue13.6%13.8%Gross profit$
26,884$
21,495Gross margin % of service revenue43.7%43.6%Total service revenue$
454,493$
355,992Total gross profit$
42,576$
4,547Gross margin % of service revenue31.4%32.2%Revenue by Geography The Americas$
231,155$
5,672Europe, Middle East & Africa161,747140,315Asia/Pacific61,59150,005Total service revenue$
454,493$
355,992Quarterly Supplemental Financial DataService revenue$
454,493$
355,992Reimbursement revenue68,95856,037Investigator fees118,05164,969Gross revenue$
41,502$
476,998Days sales outstanding3656Capital expenditures$
8,741$
,650 

 

 PAREXEL International CorporationSegment InformationUnauditedNine Months EndedNine Months Ended(in thousands)3/31/20133/31/2012Clinical Research Services (CRS)Service revenue $
960,134$
746,652% of total service revenue75.5%74.4%Gross profit$
250,671$
207,541Gross margin % of service revenue26.1%27.8%PAREXEL Consulting & Medical Communications  Services (PCMS)Service revenue$
48,236$
7,404% of total service revenue11.7%11.7%Gross profit$
59,673$
48,741Gross margin % of service revenue40.3%41.5%Perceptive Informatics (PI)Service revenue$
2,944$
39,841% of total service revenue12.8%13.9%Gross profit$
8,324$
55,897Gross margin % of service revenue41.9%40.0%Total service revenue$
,271,314$
,003,897Total gross profit$
378,668$
312,179Gross margin % of service revenue29.8%31.1%Revenue by Geography The Americas$
38,634$
443,927Europe, Middle East & Africa450,125408,306Asia/Pacific182,555151,664Total service revenue$
,271,314$
,003,897 

CONTACTS:James Winschel, Senior Vice President and Chief
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
2. PAREXEL International to Present at J.P. Morgan Healthcare Conference
3. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
4. PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs
5. PAREXEL Chairman and CEO to Deliver Keynote at MassBio CRO/CMO Symposium
6. PAREXEL International To Present At Goldman Sachs Healthcare Conference And Jefferies Healthcare Conference
7. PAREXEL International Reports First Quarter Fiscal Year 2013 Results
8. PAREXEL International to Present at Morningstar Conference
9. PAREXEL Announces Date of Third Quarter Fiscal Year 2013 Earnings Release and Conference Call
10. UV Flu Technologies Expands Its International Footprint
11. Elsevier Supports International Crisis Aid Through Pillars of Hope Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Amgen (NASDAQ: AMGN ) announced ... per share dividend for the third quarter of 2014. ... to all stockholders of record as of the close ... About Amgen Amgen is committed to unlocking the potential ... discovering, developing, manufacturing and delivering innovative human therapeutics. This ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 According to ... "Biological Drugs Market - Global Industry Analysis, Size, Share, ... biological drugs market is estimated at USD 161,056.5 million ... CAGR of 10.1% from 2014 to 2020, to reach ... , The biological drugs market is witnessing a significant ...
(Date:7/25/2014)...  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... and commercialization of a once-daily, oral therapy for the ... financial results for the period ended June 30, 2014. ... Reported cash and cash equivalents totaling $37.4 million on ... 2013.  , Reported a net loss of $3.9 ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
Breaking Biology Technology:Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4
... Microdosing or Phase 0 clinical testing has ... phase of the drug development process in the ... providers in preclinical testing and technology dependence is ... alliances, fuelling growth opportunities in this sector.(Logo: ...
... BASEL, Switzerland, Feb. 10 Syngenta today announced that ... Rice Research Institute (ARRI) of Anhui Academy of Agricultural ... conducting laboratory and field tests of novel gene functions ... optimization in key crops such as corn and soybean. ...
... CHAMPAIGN, Ill. By pushing carbon nanotubes close ... of Illinois have demonstrated a remarkable increase in ... what was previously thought possible., The researchers drove ... carries more electrons down more paths, similar to ...
Cached Biology Technology:Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma 2Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma 3Syngenta Enters Into Research Collaboration With Anhui Academy, China 2Syngenta Enters Into Research Collaboration With Anhui Academy, China 3Carbon nanotube avalanche process nearly doubles current 2
(Date:7/25/2014)... time, Spanish researchers have detected an unknown interaction between ... are introduced into a droplet of salt water and ... crystallisation to create biomineralogical biosaline 3D morphologically complex formations, ... bacteria are revived. The discovery was made by chance ... of the Astrobiology journal and may help ...
(Date:7/24/2014)... -- The Geneva Healthcare Suite, an innovative technology platform ... room wait times by an average of 92 minutes ... to a recent study published in the Academic Emergency ... suite to access data from incoming patients, implanted cardiac ... Geneva,s technology platform we have been able to quickly ...
(Date:7/24/2014)... A new study has identified two factors that ... increase the production of highly qualified physics teachers. ... to champion physics teacher education in combination with ... initiatives remain viable. Science, Technology, Engineering and Math ... and the study points the way for institutions ...
Breaking Biology News(10 mins):Bacteria manipulate salt to build shelters to hibernate 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3Creating sustainable STEM teacher preparation programs 2
... Department of Cell Biology and Histology at the University of ... boosted by means of retinoids. It was thought that this ... , Vitamin A, also known as retinol, is ... and as carotene in vegetables that have a yellow-orange colour, ...
... identified a compound that interferes with the pathogenic effects ... development of a new treatment for the disease. , ... that now afflicts 30,000 Americans, with another 150,000 at ... strikes in midlife and causes uncontrolled movements, loss of ...
... Dentistry professor has developed a calcium phosphate-based supplement that ... strength and thickness without the side effects of many ... of Biomaterials and Biomimetics and of Implant Dentistry, presented ... for Dental Research annual meeting on March 9, 2006. ...
Cached Biology News:Retinol for combating leukemia cells 2Retinol for combating leukemia cells 3MIT research holds promise for Huntington's treatment 2New study reveals promising osteoporosis treatment 2
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
... is an enhanced form of Tobacco Etch ... highly active, and significantly more stable than ... AcTEV Protease specifically recognizes a seven amino ... making it useful for removing affinity tags ...
... The Heraeus HERAcell is the ideal ... including development of ova or embryos at ... specifically designed to provide everything needed to ... , , Safe and stable incubation conditions ...
SP6 RNA Polymerase, 50 l, 20 U/l ,Cap Scribe Buffer, 100 l, 5x conc....
Biology Products: